NOVEMBER 5, 2018
The HIV prevention landscape is evolving rapidly, and the results of several ongoing HIV prevention efficacy trials -- including trials of oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines-- will have major implications for the design and conduct of the next generation of trials. This symposium will explore approaches to the statistical design of future randomized trials investigating new behavioral and biomedical HIV intervention strategies-- conducted in multiple geographic regions and at-risk populations.
The symposium will feature a series of talks given by biostatistical experts, as well as panel discussions involving clinicians, ethicists, regulators, community members, and sponsors. A series of articles, based on the talks given at the symposium, will be published in Statistical Communications in Infectious Diseases.
Attendees: Academics working in HIV prevention research, sponsor representatives, representatives of regulatory bodies, community advocates, and product developers.
Co-organized by Holly Janes and Deborah Donnell (Fred Hutchinson Cancer Research Center) and Martha Nason (NIAID)